Growth Stock Outlook 2026: AI, Biotech, and Infrastructure Lead H1 Picks
Key Takeaways
- As market volatility persists in early 2026, analysts are pivoting toward high-conviction growth plays in healthcare AI and specialized compute infrastructure.
- Key picks include Eli Lilly's pharmaceutical dominance and Nebius's explosive ARR projections, signaling a shift toward companies with proven revenue scaling.
Mentioned
Key Intelligence
Key Facts
- 1Eli Lilly's tirzepatide became the world's best-selling drug in 2025.
- 2Nebius is projected to grow its ARR from $1.25B to between $7B and $9B by the end of 2026.
- 3SoundHound AI reported 59% revenue growth in Q4 2025 despite a 60% stock price decline from its peak.
- 4Eli Lilly is expected to launch orforglipron, an oral GLP-1 drug, during the 2026 calendar year.
- 5Veeva Systems continues to dominate the life sciences cloud software sector as a core growth pick.
| Company | |||
|---|---|---|---|
| Eli Lilly (LLY) | Pharmaceuticals | Obesity/Diabetes (GLP-1) | High (Oral GLP-1 Launch) |
| Nebius (NBIS) | AI Infrastructure | Compute Scaling | Explosive ($7B-$9B ARR) |
| SoundHound AI (SOUN) | Voice AI | Enterprise Automation | Moderate-High (59% Growth) |
Analysis
The first half of 2026 has been characterized by significant equity market volatility, a trend that often drives risk-averse investors toward the sidelines. However, for venture-backed startups and growth-oriented institutional investors, this period of 'seesawing' represents a critical window to identify companies that can maintain tech-like growth rates despite macroeconomic headwinds. The current landscape is dominated by two primary themes: the 'tech-ification' of the pharmaceutical industry and the rapid scaling of generative AI infrastructure. These sectors are no longer just speculative; they are delivering concrete revenue milestones that outpace traditional market indices.
Eli Lilly (LLY) has emerged as the quintessential example of a pharmaceutical giant operating with the agility and growth profile of a high-growth tech firm. The company's dominance in the anti-obesity market, led by tirzepatide, has redefined its financial trajectory. Tirzepatide became the world's best-selling drug in 2025, and the company is now moving toward the launch of orforglipron, an oral GLP-1 drug, which is expected to hit the market in 2026. Beyond its product pipeline, Eli Lilly’s heavy investment in AI-powered drug development initiatives is setting a new standard for R&D efficiency. By integrating generative AI into the discovery and marketing phases, Lilly is positioning itself to maintain double-digit top-line growth, a rarity for a company of its scale.
Ending 2025 with an annual run rate (ARR) of $1.25 billion, the company is projected to reach between $7 billion and $9 billion by the end of 2026.
In the specialized compute and AI infrastructure space, Nebius (NBIS) is demonstrating what explosive scaling looks like in the post-2024 AI boom. Ending 2025 with an annual run rate (ARR) of $1.25 billion, the company is projected to reach between $7 billion and $9 billion by the end of 2026. This nearly 600% projected increase in ARR highlights the insatiable demand for the 'picks and shovels' of the AI era. While much of the market's attention remains on consumer-facing AI, the underlying infrastructure providers like Nebius are capturing the lion's share of enterprise spending as companies move from pilot programs to full-scale AI deployments.
What to Watch
SoundHound AI (SOUN) represents the next frontier of voice-integrated generative AI. Despite being down approximately 60% from its all-time high, the company reported a robust 59% revenue growth in Q4 2025. SoundHound’s current success in restaurant drive-thru automation serves as a proof-of-concept for much larger enterprise opportunities in medical, insurance, and financial services. The potential to replace or enhance high-cost customer service roles with audio-recognition software provides a clear path to long-term profitability, especially as the company trades at what many analysts consider a significant discount relative to its peers.
For the venture capital community, these public market trends offer a roadmap for late-stage private valuations. The success of Veeva Systems (VEEV) in providing cloud-based software specifically for life sciences further underscores the value of verticalized SaaS in a maturing market. Meanwhile, the inclusion of IonQ (IONQ) in growth discussions suggests that quantum computing is beginning to transition from a purely theoretical field to one with tangible, albeit long-term, investment appeal. As we move through 2026, the winners will be those companies that successfully bridge the gap between cutting-edge technology—whether in GLP-1 synthesis or quantum gates—and scalable, high-margin revenue models.